Back to Search
Start Over
Profiling the SARS-CoV-2-specific T-cell response.
- Source :
-
The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Aug; Vol. 24 (8), pp. e477-e478. Date of Electronic Publication: 2024 Jun 20. - Publication Year :
- 2024
-
Abstract
- Competing Interests: AS is a consultant for AstraZeneca, Calyptus Pharmaceuticals, Darwin Health, EmerVax, EUROIMMUN, F Hoffman-La Roche, Fortress Biotech, Gilead Sciences, Granite Bio, Gritstone Oncology, Guggenheim Securities, Moderna, Pfizer, RiverVest Venture Partners, and Turnstone Biologics. AG is a consultant for Pfizer. La Jolla Institute for Immunology has filed for patent protection for various aspects of T-cell epitope and vaccine design work. All other authors declare no competing interests.
Details
- Language :
- English
- ISSN :
- 1474-4457
- Volume :
- 24
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- The Lancet. Infectious diseases
- Publication Type :
- Academic Journal
- Accession number :
- 38909615
- Full Text :
- https://doi.org/10.1016/S1473-3099(24)00377-3